

William E Carson Iii

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/968933/william-e-carson-iii-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

195
papers

9,804
citations

56
h-index

92
g-index

201
ext. papers

11,172
ext. citations

6.9
avg, IF

5.81
L-index

#	Paper	IF	Citations
195	Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells. <i>Clinical Lung Cancer</i> , 2021 , 22, e487-e497	4.9	2
194	The gut connection: Intestinal permeability as a pathway from breast cancer survivors' relationship satisfaction to inflammation across treatment. <i>Brain, Behavior, and Immunity</i> , 2021 , 100, 145-154	16.6	2
193	In Situ Deployment of Engineered Extracellular Vesicles into the Tumor Niche via Myeloid-Derived Suppressor Cells. <i>Advanced Healthcare Materials</i> , 2021 , e2101619	10.1	2
192	CD200 Blockade Modulates Tumor Immune Microenvironment but Fails to Show Efficacy in Inhibiting Tumor Growth in a Murine Model of Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 739816	5.7	1
191	Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma. <i>Frontiers in Immunology</i> , 2021 , 12, 740890	8.4	1
190	Antibody Conjugation of Fluorescent Nanodiamonds for Targeted Innate Immune Cell Activation. <i>ACS Applied Nano Materials</i> , 2021 , 4, 3122-3139	5.6	3
189	Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 2439-2451	7.4	9
188	Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. <i>Blood</i> , 2021 , 137, 3473-3483	2.2	15
187	Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 435.e17-435.e22	2.8	0
186	Breast cancer survivors' satisfying marriages predict better psychological and physical health: A longitudinal comparison of satisfied, dissatisfied, and unmarried women. <i>Psycho-Oncology</i> , 2021 , 30, 699-707	3.9	4
185	Observations on the use of Bruton's tyrosine kinase inhibitors in SARS-CoV-2 and cancer. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 15	22.4	4
184	Loss of miR-1469 expression mediates melanoma cell migration and invasion. <i>PLoS ONE</i> , 2021 , 16, e0256679	6.79	0
183	Characterization of inflammatory changes in the breast cancer associated adipose tissue and comparison to the unaffected contralateral breast. <i>Surgical Oncology</i> , 2021 , 39, 101659	2.5	
182	Reciprocal Signaling between Myeloid Derived Suppressor and Tumor Cells Enhances Cellular Motility and is Mediated by Structural Cues in the Microenvironment. <i>Advanced Biology</i> , 2020 , 4, e2000049	2.5	3
181	Guided migration analyses at the single-clone level uncover cellular targets of interest in tumor-associated myeloid-derived suppressor cell populations. <i>Scientific Reports</i> , 2020 , 10, 1189	4.9	3
180	NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 120-131	7.3	3
179	Relationship satisfaction predicts lower stress and inflammation in breast cancer survivors: A longitudinal study of within-person and between-person effects. <i>Psychoneuroendocrinology</i> , 2020 , 118, 104708	5	14

178	Within-person changes in cancer-related distress predict breast cancer survivors' inflammation across treatment. <i>Psychoneuroendocrinology</i> , 2020 , 121, 104866	5	5
177	Tissue microRNA expression profiling in hepatic and pulmonary metastatic melanoma. <i>Melanoma Research</i> , 2020 , 30, 455-464	3.3	2
176	Soy-tomato enriched diet reduces inflammation and disease severity in a pre-clinical model of chronic pancreatitis. <i>Scientific Reports</i> , 2020 , 10, 21824	4.9	3
175	Evidence for interaction of the NLRP3 inflammasome and Bruton's tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1beta. <i>Onc Immunology</i> , 2019 , 8, 1659704	7.2	6
174	Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro 2019 , 7, 140		54
173	A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019 , 25, 4955-4965	12.9	16
172	Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function. <i>Scientific Reports</i> , 2019 , 9, 5068	4.9	24
171	Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature. <i>Hereditary Cancer in Clinical Practice</i> , 2019 , 17, 12	2.3	14
170	A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 619-629	7.4	4
169	An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1379-1389	7.4	15
168	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 367-402	7.3	195
167	Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy. <i>Melanoma Research</i> , 2019 , 29, 491-500	3.3	3
166	Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON. <i>Cancer Immunology Research</i> , 2018 , 6, 671-684	12.5	15
165	Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function. <i>Clinical Cancer Research</i> , 2018 , 24, 1891-1904	12.9	109
164	Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 5534-5539	11.5	40
163	Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2018 , 118, 501-509	2.8	14
162	Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma. <i>Melanoma Research</i> , 2018 , 28, 390-397	3.3	4
161	Concurrent phyllodes tumor, eccrine carcinoma, and multinodular goiter 20 years after radiotherapy for Hodgkin lymphoma. <i>Clinical Case Reports (discontinued)</i> , 2018 , 6, 2498-2503	0.7	

160	Unusual recurrence of breast cancer in a BRCA-variant patient after fat grafting. <i>Clinical Case Reports (discontinued)</i> , 2018 , 6, 2457-2462	0.7	1
159	Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017 , 13, 909-920	6	21
158	Phase III Randomized Study of 4 Weeks of High-Dose Interferon- γ in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). <i>Journal of Clinical Oncology</i> , 2017 , 35, 885-892	2.2	34
157	Novel rodent model of breast cancer survival with persistent anxiety-like behavior and inflammation. <i>Behavioural Brain Research</i> , 2017 , 330, 108-117	3.4	20
156	Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging?. <i>Journal of Clinical Oncology</i> , 2017 , 35, 149-156	2.2	45
155	Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2028-2036	2.2	72
154	Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 9629-9634	11.5	12
153	Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 1437-1447	7.4	44
152	MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions. <i>Cancer Immunology Research</i> , 2017 , 5, 778-789	12.5	12
151	Nitric oxide mediated inhibition of antigen presentation from DCs to CD4 T cells in cancer and measurement of STAT1 nitration. <i>Scientific Reports</i> , 2017 , 7, 15424	4.9	37
150	Activation of the Fc γ 3R1 on human natural killer cells leads to increased expression of functional interleukin-21 receptor. <i>Oncotarget</i> , 2017 , 6, e1312045	7.2	2
149	Classification of Indeterminate Melanocytic Lesions by MicroRNA Profiling. <i>Annals of Surgical Oncology</i> , 2017 , 24, 347-354	3.1	9
148	Trajectories of Stress, Depressive Symptoms, and Immunity in Cancer Survivors: Diagnosis to 5 Years. <i>Clinical Cancer Research</i> , 2017 , 23, 52-61	12.9	28
147	IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. <i>Clinical Cancer Research</i> , 2017 , 23, 489-502	12.9	32
146	Plasma MicroRNA Levels Following Resection of Metastatic Melanoma. <i>Bioinformatics and Biology Insights</i> , 2017 , 11, 1177932217694837	5.3	20
145	Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer. <i>Oncotarget</i> , 2017 , 8, 1481-1494	3.3	21
144	A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2244-50	6.1	19
143	Interferon- γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells. <i>Journal of Biological Chemistry</i> , 2016 , 291, 25656-25666	5.4	11

142	Structural characterization of NRAS isoform 5. <i>Protein Science</i> , 2016 , 25, 1069-74	6.3	4
141	MicroRNA dysregulation in melanoma. <i>Surgical Oncology</i> , 2016 , 25, 184-9	2.5	41
140	Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function. <i>Journal of Biological Chemistry</i> , 2016 , 291, 3043-52	5.4	48
139	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. <i>Cancer Research</i> , 2016 , 76, 2125-36	10.1	121
138	NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines. <i>Cancer Immunology Research</i> , 2016 , 4, 323-336	12.5	2
137	A Comprehensive Program for the Enhancement of Accrual to Clinical Trials. <i>Annals of Surgical Oncology</i> , 2016 , 23, 2146-52	3.1	9
136	The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. <i>Oncotarget</i> , 2016 , 7, 81172-81186	3.3	6
135	MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. <i>OncoTargets and Therapy</i> , 2016 , 9, 5931-5941	4.4	3
134	A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma. <i>Journal of Immunology</i> , 2016 , 197, 1489-97	5.3	18
133	NKp80 Defines a Critical Step during Human Natural Killer Cell Development. <i>Cell Reports</i> , 2016 , 16, 379-396	10.6	68
132	Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 450-73	7.3	165
131	NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 945-58	7.3	66
130	Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions. <i>Melanoma Research</i> , 2016 , 26, 329-37	3.3	9
129	Fluorescent nanodiamonds and their use in biomedical research 2016 ,		3
128	A Progenitor Cell Expressing Transcription Factor RORγ Generates All Human Innate Lymphoid Cell Subsets. <i>Immunity</i> , 2016 , 44, 1140-50	32.3	125
127	A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-β in patients with CEA-expressing carcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 1353-1364	7.4	19
126	Global microRNA profiling for diagnostic appraisal of melanocytic Spitz tumors. <i>Journal of Surgical Research</i> , 2016 , 205, 350-358	2.5	14
125	Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator. <i>Oncolmmunology</i> , 2016 , 5, e1214787	7.2	19

124	The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. <i>Journal of Immunology</i> , 2015 , 195, 1995-2005	5.3	24
123	Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis. <i>American Journal of Roentgenology</i> , 2015 , 205, W283-93	5.4	38
122	Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology. <i>ACS Nano</i> , 2015 , 9, 9731-40	16.7	177
121	ASCO 2015 update on melanoma. <i>Surgical Oncology</i> , 2015 , 24, 363-5	2.5	4
120	Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy. <i>Surgical Oncology</i> , 2015 , 24, 353-8	2.5	32
119	MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E6744-51	11.5	14
118	NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 1337-46	7.3	14
117	Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12. <i>BMC Medical Genomics</i> , 2015 , 8, 66	3.7	13
116	Surgical management of ovarian carcinoma metastatic to the breast and axilla: A role for metastasectomy?. <i>Journal of Surgical Oncology</i> , 2015 , 112, 581-4	2.8	4
115	MiR-21 enhances melanoma invasiveness via inhibition of tissue inhibitor of metalloproteinases 3 expression: in vivo effects of MiR-21 inhibitor. <i>PLoS ONE</i> , 2015 , 10, e0115919	3.7	68
114	Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer. <i>Molecular Oncology</i> , 2015 , 9, 906-19	7.9	108
113	Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 149-59	7.4	83
112	PTEN is a negative regulator of NK cell cytolytic function. <i>Journal of Immunology</i> , 2015 , 194, 1832-40	5.3	28
111	RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. <i>Cancer Research</i> , 2015 , 75, 974-85	10.1	86
110	Signaling pathways involved in MDSC regulation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1846, 55-65	11.2	112
109	Attachment anxiety is related to Epstein-Barr virus latency. <i>Brain, Behavior, and Immunity</i> , 2014 , 41, 232-86.6	8.6	36
108	NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 4179-84	11.5	19
107	Social support predicts inflammation, pain, and depressive symptoms: longitudinal relationships among breast cancer survivors. <i>Psychoneuroendocrinology</i> , 2014 , 42, 38-44	5	85

106	Melanoma, version 4.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 621-93	52
105	Pain, depression, and fatigue: loneliness as a longitudinal risk factor. <i>Health Psychology</i> , 2014 , 33, 948-575	173
104	Tumor Infiltrating Lymphocytes - The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2014 , 5,	1 2
103	Cognitive problems among breast cancer survivors: loneliness enhances risk. <i>Psycho-Oncology</i> , 2014 , 23, 1356-64	3.9 27
102	Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab. <i>Radiology</i> , 2014 , 270, 425-34	20.5 22
101	A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma. <i>Journal of Immunotherapy</i> , 2014 , 37, 180-6	5 9
100	A phase I trial of bortezomib and interferon- β in metastatic melanoma. <i>Journal of Immunotherapy</i> , 2014 , 37, 55-62	5 10
99	Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway. <i>Science Signaling</i> , 2014 , 7, ra36	8.8 16
98	Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. <i>Cancer Immunology Research</i> , 2014 , 2, 981-7	12.5 8
97	Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer 2013 , 1, 10	215
96	Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells. <i>Veterinary Immunology and Immunopathology</i> , 2013 , 153, 249-59	2 34
95	Cytokine signaling-1 suppressor is inducible by IL-1beta and inhibits the catabolic effects of IL-1beta in chondrocytes: its implication in the paradoxical joint-protective role of IL-1beta. <i>Arthritis Research and Therapy</i> , 2013 , 15, R191	5.7 17
94	Heparin-binding EGF-like growth factor (HB-EGF) protects the intestines from radiation therapy-induced intestinal injury. <i>Journal of Pediatric Surgery</i> , 2013 , 48, 1316-22	2.6 13
93	Review of S100A9 biology and its role in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013 , 1835, 100-9	11.2 77
92	A nanoporous cell-therapy device with controllable biodegradation for long-term drug release. <i>Journal of Controlled Release</i> , 2013 , 165, 226-33	11.7 13
91	Myeloid-derived suppressor cells in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 140, 13-24	118
90	Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. <i>Psycho-Oncology</i> , 2013 , 22, 1889-94	3.9 24
89	Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. <i>Journal of Clinical Oncology</i> , 2013 , 31, 30-8	2.2 87

88	Melanoma, version 2.2013: featured updates to the NCCN guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 395-407	7.3	112
87	Social support and socioeconomic status interact to predict Epstein-Barr virus latency in women awaiting diagnosis or newly diagnosed with breast cancer. <i>Health Psychology</i> , 2012 , 31, 11-9	5	33
86	Impact of breast cancer recurrence and cancer-specific stress on spouse health and immune function. <i>Brain, Behavior, and Immunity</i> , 2012 , 26, 228-33	16.6	17
85	Fatigue and herpesvirus latency in women newly diagnosed with breast cancer. <i>Brain, Behavior, and Immunity</i> , 2012 , 26, 394-400	16.6	28
84	Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival. <i>Experimental Eye Research</i> , 2012 , 100, 26-31	3.7	35
83	Adrenergic receptor mediated increases in activation and function of natural killer cells following repeated social disruption. <i>Brain, Behavior, and Immunity</i> , 2012 , 26, 1226-38	16.6	32
82	Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. <i>Surgery</i> , 2012 , 152, 431-40	3.6	49
81	Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. <i>OncolImmunology</i> , 2012 , 1, 1048-1060	7.2	29
80	Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer. <i>OncolImmunology</i> , 2012 , 1, 1004-1016	7.2	19
79	BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 34-41	2.2	142
78	Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation. <i>Journal of Immunotherapy</i> , 2012 , 35, 367-73	5	24
77	Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 366-400	7.3	53
76	NK cell-based immunotherapy for treating cancer: will it be promising?. <i>The Korean Journal of Hematology</i> , 2011 , 46, 3-5		17
75	A pilot study of bevacizumab and interferon- β in ocular melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011 , 34, 87-91	2.7	15
74	A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. <i>Journal of Immunotherapy</i> , 2011 , 34, 509-15	5	39
73	Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment. <i>Journal of Controlled Release</i> , 2011 , 151, 239-45	11.7	17
72	Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. <i>Cellular Immunology</i> , 2011 , 270, 80-7	4.4	64
71	Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 1269-79	7.4	108

70	Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4+ and CD8+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 1281-8	7.4	17
69	Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. <i>Cancer Research</i> , 2011 , 71, 5101-10	10.1	144
68	IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN- γ production. <i>Journal of Immunology</i> , 2011 , 186, 3401-9	5.3	80
67	Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy. <i>Clinical Cancer Research</i> , 2010 , 16, 2065-75	12.9	31
66	Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 510-20	6.1	36
65	Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants. <i>Clinical Cancer Research</i> , 2010 , 16, 3270-8	12.9	121
64	The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. <i>Molecular Cancer</i> , 2010 , 9, 165	42.1	89
63	Folate-immunoglobulin G as an anticancer therapeutic antibody. <i>Bioconjugate Chemistry</i> , 2010 , 21, 961-86.3		14
62	Braking bad: blockade of inhibitory pathways improves interleukin-15 therapy. <i>Clinical Cancer Research</i> , 2010 , 16, 5917-9	12.9	1
61	Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. <i>BMC Cancer</i> , 2010 , 10, 142	4.8	39
60	A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2983-91	6.1	77
59	A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2009 , 117, 83-9	4.4	33
58	Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 2031-7	7.4	6
57	Immune modulation with interleukin-21. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1182, 39-46	6.5	10
56	Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5270-7	2.2	63
55	A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: secondary analysis of a randomized controlled trial. <i>Psychosomatic Medicine</i> , 2009 , 71, 715-24	3.7	84
54	Giant breast tumors: surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature. <i>World Journal of Surgical Oncology</i> , 2008 , 6, 117	3.4	49
53	Biphasic anaphylactic reaction to blue dye during sentinel lymph node biopsy. <i>World Journal of Surgical Oncology</i> , 2008 , 6, 79	3.4	20

52	VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. <i>Journal of Interferon and Cytokine Research</i> , 2008 , 28, 553-61	3.5	25
51	IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. <i>Cancer Research</i> , 2008 , 68, 8351-60	10.1	46
50	IFN-alpha-2b-induced signal transduction and gene regulation in patient peripheral blood mononuclear cells is not enhanced by a dose increase from 5 to 10 megaunits/m2. <i>Clinical Cancer Research</i> , 2008 , 14, 1438-45	12.9	12
49	Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha. <i>Clinical Cancer Research</i> , 2008 , 14, 5900-6	12.9	29
48	Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma. <i>Blood</i> , 2008 , 111, 4173-83	2.2	69
47	IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. <i>Blood</i> , 2008 , 111, 4723-30	2.2	79
46	Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 1137-49	7.4	10
45	Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 1471-81	7.4	39
44	Delayed emotional recovery after taxane-based chemotherapy. <i>Cancer</i> , 2008 , 113, 638-47	6.4	41
43	Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. <i>Cancer</i> , 2008 , 113, 3450-8	6.4	316
42	Re-emphasizing the concept of adequacy of intraoperative assessment of the axillary sentinel lymph nodes for identifying nodal positivity during breast cancer surgery. <i>World Journal of Surgical Oncology</i> , 2007 , 5, 18	3.4	18
41	Immunotherapy comes of age: overview of the 21st Annual Meeting and associated programs of the International Society for Biological Therapy of Cancer. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 419-422	5.4	
40	A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. <i>Annals of Surgical Oncology</i> , 2007 , 14, 2367-76	3.1	125
39	STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alpha. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1845-52	7.4	31
38	Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells. <i>Clinical Cancer Research</i> , 2007 , 13, 5010-9	12.9	34
37	The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. <i>Clinical Cancer Research</i> , 2007 , 13, 6419-28	12.9	118
36	Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. <i>Brain, Behavior, and Immunity</i> , 2007 , 21, 185-94	16.6	53
35	Distress reduction from a psychological intervention contributes to improved health for cancer patients. <i>Brain, Behavior, and Immunity</i> , 2007 , 21, 953-61	16.6	135

34	Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobulin-like receptors. <i>Journal of Surgical Research</i> , 2007 , 139, 36-44	2.5	32
33	Current immunotherapeutic strategies in breast cancer. <i>Surgical Oncology Clinics of North America</i> , 2007 , 16, 841-60, ix	2.7	4
32	Precancerous stem cells have the potential for both benign and malignant differentiation. <i>PLoS ONE</i> , 2007 , 2, e293	3.7	84
31	Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects. <i>Surgery</i> , 2006 , 140, 297-306	3.6	10
30	Interleukin-21 enhances NK cell activation in response to antibody-coated targets. <i>Journal of Immunology</i> , 2006 , 177, 120-9	5.3	104
29	Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. <i>Cancer Research</i> , 2006 , 66, 517-26	10.1	98
28	Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. <i>Clinical Cancer Research</i> , 2006 , 12, 5850-8	12.9	27
27	FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways. <i>Blood</i> , 2006 , 108, 718-25	2.2	29
26	Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. <i>Journal of Immunotherapy</i> , 2006 , 29, 95-101	5	23
25	Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. <i>Annals of Surgical Oncology</i> , 2006 , 13, 1412-21	3.1	68
24	Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. <i>Blood</i> , 2005 , 105, 3011-8	2.2	68
23	Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 815-25	7.4	27
22	Release of biologically functional interferon-alpha from a nanochannel delivery system. <i>Biomedical Microdevices</i> , 2005 , 7, 71-9	3.7	49
21	Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8835-44	2.2	23
20	Getting melanoma cells to stimulate with frequency. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8929-31	2.2	5
19	CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. <i>Journal of Immunology</i> , 2005 , 175, 1619-27	5.3	96
18	Src homology 2-containing inositol 5Sphosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12. <i>Cancer Research</i> , 2005 , 65, 9099-107	10.1	20
17	Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 1331-42	9.7	67

16	Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3570-80	2.2	306
15	Cellular immunity in breast cancer patients completing taxane treatment. <i>Clinical Cancer Research</i> , 2004 , 10, 3401-9	12.9	81
14	A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. <i>Clinical Cancer Research</i> , 2004 , 10, 5027-37	12.9	93
13	A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. <i>Journal of Immunology</i> , 2003 , 170, 4242-53	5.3	59
12	Patterns of recurrence after sentinel lymph node biopsy for breast cancer. <i>Annals of Surgical Oncology</i> , 2003 , 10, 376-80	3.1	50
11	The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. <i>Journal of Clinical Investigation</i> , 2003 , 112, 170-80	15.9	91
10	IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. <i>Journal of Clinical Investigation</i> , 2002 , 110, 983-992	15.9	123
9	IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. <i>Journal of Clinical Investigation</i> , 2002 , 110, 983-92	15.9	94
8	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. <i>European Journal of Immunology</i> , 2001 , 31, 3016-25	6.1	129
7	Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. <i>Blood</i> , 2001 , 97, 3146-51	2.2	1023
6	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 / neu-positive breast cancer cells 2001 , 31, 3016		3
5	CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. <i>European Journal of Immunology</i> , 1997 , 27, 354-60	6.1	90
4	Interleukin 15: a potential player during the innate immune response to infection. <i>Experimental Parasitology</i> , 1996 , 84, 291-4	2.1	13
3	Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. <i>Journal of Biological Chemistry</i> , 1996 , 271, 13968-75	5.4	76
2	Rat Mitogen-Stimulated Lymphokine-Activated T Killer Cells. <i>Journal of Immunotherapy</i> , 1991 , 10, 131-140		8
1	Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma. <i>Journal of Immunological Methods</i> , 1991 , 137, 225-35	2.5	9